^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-8068

    i
    Other names: SHR-8068, SHR8068, SHR 8068
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4d
    A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    SHR-A2102 • Ariely (adebrelimab) • SHR-8068
    9d
    SHR-8068-301: Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=560, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Ariely (adebrelimab) • SHR-8068
    10d
    A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=124, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SHR-A2102 • Ariely (adebrelimab) • SHR-8068
    29d
    SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study. (PubMed, Front Immunol)
    This proof-of-concept study would provide safety and efficacy signals of this novel combination treatment for the MSS CRCs in the late-line setting. And it may offer new insights on the clinical application of dual immunotherapy combined with anti-angiogenic therapy in the MSS CRC.
    Clinical protocol • P1/2 data • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • Airuituo (bevacizumab biosimilar) • Ariely (adebrelimab) • SHR-8068
    1m
    A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    SHR-A2102 • Ariely (adebrelimab) • SHR-8068
    2ms
    Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=560, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P3 trial
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Ariely (adebrelimab) • SHR-8068
    2ms
    A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=124, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    SHR-A2102 • Ariely (adebrelimab) • SHR-8068
    4ms
    Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer (clinicaltrials.gov)
    P2, N=240, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=120 --> 240 | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Feb 2025 --> Jun 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • paclitaxel • capecitabine • oxaliplatin • Ariely (adebrelimab) • SHR-8068
    5ms
    Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    cisplatin • gemcitabine • Ariely (adebrelimab) • SHR-8068
    5ms
    Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=129, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Avastin (bevacizumab) • Ariely (adebrelimab) • SHR-8068
    5ms
    Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P2 trial • Combination therapy • Metastases
    |
    cisplatin • gemcitabine • Ariely (adebrelimab) • SHR-8068
    6ms
    Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC (clinicaltrials.gov)
    P1/2, N=124, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    carboplatin • Ariely (adebrelimab) • SHR-8068 • SHR-A1921
    7ms
    SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, West China Hospital
    New P1/2 trial • Metastases
    |
    Avastin (bevacizumab) • Ariely (adebrelimab) • SHR-8068
    8ms
    Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • paclitaxel • capecitabine • oxaliplatin • Ariely (adebrelimab) • SHR-8068
    9ms
    Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P2 trial • Metastases
    |
    cisplatin • paclitaxel • capecitabine • oxaliplatin • Ariely (adebrelimab) • SHR-8068
    over2years
    Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=168, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • paclitaxel • Ariely (adebrelimab) • SHR-8068
    over2years
    Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=168, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • paclitaxel • Ariely (adebrelimab) • SHR-8068